Clinico-pathological correlation between deep vein thrombosis and malignancy

Nirav Chhabhaya; Jayesh Patel; Ravi Bhatt; Chetan Agarwal

doi:10.18203/2349-2902.isj20230972

Authors

Nirav Chhabhaya Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Jayesh Patel Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Ravi Bhatt Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
Chetan Agarwal Department of Surgery, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India

DOI:

https://doi.org/10.18203/2349-2902.isj20230972

Keywords:

DVT, Cancer, Blood clot, Chemotherapy, Radiotherapy, Comorbidity

Abstract

Background: Cancer is one of the risk factors with estimates suggesting annual incidence of venous thrombo-embolism (VTE) is 0.5% in cancer patients compared to 0.1% in the general population. VTE is the second most common cause of death from cancer. Cancer associated thrombosis (CAT) is the target of intense interest in recent medical literature, including its epidemiology, pathophysiology, challenges in diagnosis, prophylaxis and treatment. Cancer types, stages, treatment and comorbidities are among the risk factors for developing VTE.

Methods: This was a retrospective study based on patient hospital records from May 2017 to Dec 2021. About 50 patient records reportedly having CAT were studied to meet research objectives. Data pertaining to patient age, gender and comorbidity was collected for study purpose. Patients having confirmed diagnosis for deep venous thrombosis (DVT) (Duplex scan) and malignancy (Biopsy) were considered to ensure data completeness for analysis and reporting.

Results: Our study showed that there was no correlation between different types of cancer with deep venous thrombosis, neither with different approach of treatment had it showed any significant results nor with any comorbidity. But we found out a correlation between different cancer with various comorbidity.

Conclusions: Our study aimed at exploring clinical and pathological correlation between DVT and malignancy. Our study was a sincere effort to study clinic-pathological correlation among cancer patients with known cases of venous thrombosis. Further studies are warranted with large sample and more extensive case record format, and preferably long-term follow-up to understand patient outcome.

Metrics

Metrics Loading ...

References

Thompson AE. Deep Vein Thrombosis. JAMA. 2015;313(20):2090.

Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:129-37.

Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP et al. Cancer-associated thrombosis: the when, how, and why. Eur Respir Rev. 2019;28(151):180119.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-82.

Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-31.

Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33-53.

Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res. 2012;129(1):10-5.

Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-22.

Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125(2):1-7.

Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401-10.

Prandoni P, Lensing AW, Büller HR,etal. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327(16):1128-33.

Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839-47.

Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72(2):89-93.

Winter PC. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol. 2006;24:126-33.

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27:4919-26.

JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011;75:1258-81.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-23.

White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93(2):298-305.

Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M, RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131(1):24-30.

Vormittag R, Simanek R, Ay C. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009;29(12):2176-81.

Imberti D, Agnelli G, Ageno W. MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica. 2008;93(2):273-278.